PRODUCT INFORMATION

HQL-79
Item No. 10134

CAS Registry No.: 162641-16-9
Formal Name: 4-(diphenylmethoxy)-1-[3-(1H-tetrazol-5-yl)propyl]-piperidine
MF: C_{22}H_{27}N_{5}O
FW: 377.5
Purity: ≥98%
Stability: ≥1 year at -20˚C
Supplied as: A crystalline solid

Laboratory Procedures

For long term storage, we suggest that HQL-79 be stored as supplied at -20˚C. It should be stable for at least one year.

HQL-79 is supplied as a crystalline solid. A stock solution may be made by dissolving the HQL-79 in an organic solvent purged with an inert gas. HQL-79 is soluble in organic solvents such as methanol. The solubility of HQL-79 in methanol is approximately 2.5 mg/ml.

Further dilutions of the organic solvent solution into aqueous buffers or isotonic saline should be made prior to performing biological experiments. Ensure that the residual amount of organic solvent is insignificant, since organic solvents may have physiological effects at low concentrations.

Description

HQL-79 is a selective inhibitor of hematopoietic prostaglandin D (PGD) synthase. Structurally, it is a synthetic tetrazole compound originally prepared as a possible antihistamine.\(^1\) Subsequent evaluation in models of allergy and asthma demonstrates the HQL-79 is orally available, and inhibits the synthesis of PGD\(_2\) (Item No. 12010).\(^2\) HQL-79 is thus a likely lead compound for the preparation of potent, selective hematopoietic PGD synthase inhibitors.

References